Gustafsson Finn, Guarracino Fabio, Schwinger Robert H G
Department of Cardiology, Rigshospitalet, Copenhagen, Denmark.
Department of Cardiothoracic Anesthesia and Intensive Care Medicine, Azienda Ospedaliero Universitaria Pisana, Pisa, Italy.
Eur Heart J Suppl. 2017 Mar;19(Suppl C):C2-C7. doi: 10.1093/eurheartj/sux001. Epub 2017 Mar 8.
Levosimendan is an inodilator developed for treatment of acute heart failure. It was shown to enhance cardiac contractility, and to exert a vasodilatory effect in all vascular beds. In some trials, the use of levosimendan was associated with cardioprotective effects. These distinctive qualities may be relevant to its use in a range of acute heart failure settings and/or complications, including acute coronary syndromes and cardiogenic shock. It is conjectured that part of the benefit of levosimendan may arise from restoration of ventriculo-arterial coupling via optimization of the ratio of arterial to ventricular elastance and the transfer of mechanical energy. Full confirmation of the effectiveness of levosimendan is still awaited in many of these scenarios; however, the range of potential applications highlights both the versatility of levosimendan and the relative lack of proven interventions in many of these situations.
左西孟旦是一种开发用于治疗急性心力衰竭的血管活性药物。它能增强心肌收缩力,并在所有血管床发挥血管舒张作用。在一些试验中,使用左西孟旦具有心脏保护作用。这些独特的特性可能与其在一系列急性心力衰竭情况和/或并发症中的应用有关,包括急性冠状动脉综合征和心源性休克。据推测,左西孟旦的部分益处可能源于通过优化动脉与心室弹性比值以及机械能传递来恢复心室动脉耦联。在许多这些情况下,左西孟旦有效性的充分证实仍有待观察;然而,潜在应用范围既凸显了左西孟旦的多功能性,也表明在许多这些情况下相对缺乏经过验证的干预措施。